Go Pro
NASDAQ:BOLD

Boundless Bio Q3 2024 Earnings Report

Boundless Bio logo
$2.70 -0.18 (-6.25%)
Closing price 04:00 PM Eastern
Extended Trading
$2.72 +0.01 (+0.56%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boundless Bio EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.76
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Boundless Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Boundless Bio Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
4:00PM ET

Boundless Bio Earnings Headlines

My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
See More Boundless Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email.

About Boundless Bio

Boundless Bio (NASDAQ:BOLD) is a clinical-stage biotechnology company focused on developing targeted medicines for patients with oncogene-amplified cancers. The company’s research centers on extrachromosomal DNA (ecDNA), circular DNA structures found outside chromosomes that can contain multiple copies of cancer-driving genes and contribute to tumor growth, treatment resistance and disease progression.

Boundless Bio uses its proprietary Spyglass platform to identify and characterize ecDNA and discover potential drug targets. Its pipeline includes ecDNA-directed small-molecule therapies designed to selectively disrupt the biology of tumors that depend on oncogene amplification. The company is advancing these programs through preclinical research and clinical development in solid tumors.

Founded in 2018 and headquartered in San Diego, California, Boundless Bio serves the global oncology research and biopharmaceutical markets through its drug-discovery and development efforts. The company became publicly traded on the Nasdaq under the symbol BOLD in 2024.

View Boundless Bio Profile